{"id":"sinemet-comparator","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dyskinesia"},{"rate":"20-30","effect":"Motor fluctuations"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"5-10","effect":"Hallucinations"},{"rate":"5-10","effect":"Confusion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is converted to dopamine in the brain to replace depleted dopamine in Parkinson's disease. Carbidopa inhibits the enzyme aromatic L-amino acid decarboxylase in the periphery, preventing premature conversion of levodopa to dopamine outside the brain, thereby increasing the amount of levodopa available to cross the blood-brain barrier and reducing peripheral side effects.","oneSentence":"Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:10.895Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication"}]},"trialDetails":[{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT00590122","phase":"PHASE4","title":"Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT01171313","phase":"PHASE2","title":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2010-07","conditions":"Parkinson's Disease","enrollment":35},{"nctId":"NCT00974974","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-09","conditions":"Parkinson's Disease","enrollment":471},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":"Chronic Back Pain","enrollment":""},{"nctId":"NCT00869791","phase":"PHASE2","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2008-11","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT01130493","phase":"PHASE3","title":"A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2010-05","conditions":"Parkinson's Disease","enrollment":110},{"nctId":"NCT01429077","phase":"PHASE2, PHASE3","title":"Augmenting Language Therapy for Aphasia: Levodopa","status":"COMPLETED","sponsor":"Shirley Ryan AbilityLab","startDate":"2007-10","conditions":"Nonfluent Aphasia, Stroke","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Long acting levodopa","Sinemet CR 250' (Levodopa 200mg, and 50mg carbidopa)","Levodopa","IR CD-LD Tablets","carbidopa/levodopa"],"phase":"marketed","status":"active","brandName":"Sinemet (comparator)","genericName":"Sinemet (comparator)","companyName":"XenoPort, Inc.","companyId":"xenoport-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa. Used for Parkinson's disease, Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}